Skip to main content

MS stem cell transplants mostly done without admission

By MS Buddy ·

Summarized from Transplantation and cellular therapy, Nov 2026 · PubMed. AI-generated summary. Not medical advice.

Review · published reports from a stem cell transplant program for MS

Research by María Fernanda García-Plata, Guillermo José Ruiz-Argüelles and 8 colleagues at Clínica Ruiz.

What does a Mexican MS stem cell transplant program show about safety and benefits?

Key Takeaway

A review of one MS stem cell transplant program found most procedures avoided hospital admission, but treatment benefits need independent, controlled research.

Rounded stem cells with visible nuclei float against a muted blue-gray background.
Credibility
Interest
Share:1 min read

What They Found

One analysis covered 1,700 transplant recipients, including 1,667 people with MS; about 97% completed treatment without hospital admission. Within 28 days, about 0.2% died and about 3% had medical complications. In a group of 617 people, about 78% reported stable or improved disability scores after 12 months. Another report found similar disability responses below and above age 60, but more early complications in older people. The review's strongest evidence concerned whether this program could deliver treatment and its short-term safety, rather than comparisons with other treatments.

Who Should Care and Why

This review examined published reports from a Mexican stem cell transplant program treating people with MS. The treatment used each person's own blood-forming stem cells. Most procedures took place without hospital admission. The review also examined recovery, side effects, and outcomes reported by patients. Whether these findings apply elsewhere remains uncertain, especially for progressive MS.

Important Considerations

This was a review of 34 published sources, not a controlled trial. Groups overlapped across reports, so participant counts were not added; the largest analysis described included 1,700 recipients. Independent, controlled research is needed to compare benefits and assess whether findings apply beyond this program.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Transplantation and cellular therapy by et al.. Reproduced from the PubMed record.

The HSCT-Mexico program has reported outpatient autologous hematopoietic stem cell transplantation (aHSCT) for multiple sclerosis (MS) using refrigerated non-cryopreserved grafts, split-dose cyclophosphamide, and post-engraftment rituximab. To provide a critical, question-based synthesis of the program's published experience and identify lessons not covered by its 2021 milestone report. Thirty-two originally supplied institutional publications, one 2025 ASH abstract, and one peer-reviewed 2026 correspondence identified during revision (34 published sources, 2016-2026) were narratively reviewed. Overlapping cohorts were not pooled. Five independent international sources were used for external context. Across sequential program cohorts, outpatient completion and short-term safety were documented; a 1,700-recipient analysis (1,667 with MS) reported 96.6% fully outpatient procedures, 0.17% 28-day mortality, and 3.3% 28-day morbidity. Approximately 78% had stable or improved patient-reported Expanded Disability Status Scale (EDSS) scores at 12 months in a 617-person cohort. A 1,438-person ASH abstract found similar favorable EDSS response below and at or above age 60 (75.2% vs 76.9%; p=0.64), but more early complications in the older group (5.8% vs 2.1%; p=0.02). Studies additionally addressed hematologic recovery, toxicity, surveillance, candidate prognostic factors, and patient-centered outcomes. This synthesis extends the 2021 milestone report through 2026 by explicitly distinguishing overlapping datasets, clinical observations, and exploratory associations. Its strongest evidence concerns program-specific feasibility and short-term safety; efficacy comparisons and generalization, especially in progressive MS, require independent controlled research.

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Paper nerve branches sit within a curved protective layer, with most small paper shapes outside and a few nearby.
Stem cell transplants curb disease activity in active MS

11/19/2026

A review finds lasting control of disease activity after stem cell transplants in selected people wi

Read More
Two curving ribbons, one with fewer loose knots; the knots on both ribbons are the same size and length.
MS drugs cut relapses but did not change relapse recovery

11/19/2026

Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan

Read More
Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
Muted blue paths widen and join across soft gray layers on an off-white background.
MS treatment in Poland started sooner, reached more people

11/13/2026

From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.